New Product

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 11
Volume 15
Issue 11

BioLucent, Inc. has received 510(k)clearance from the FDA for its SAVIapplicator. The SAVI device offersa multicatheter, single-entry approachto breast brachytherapy.

ALISO VIEJO, California--BioLucent, Inc. has received 510(k)clearance from the FDA for its SAVIapplicator. The SAVI device offersa multicatheter, single-entry approachto breast brachytherapy.SAVI combines the tissue-sparingdosimetry of interstitial brachytherapywith the single-entry easeof intracavitary ("balloon") brachytherapy,the company said in a pressrelease

The applicator is for use in acceleratedpartial breast irradiation(APBI) treatment following alumpectomy. The device includesan expandable bundle of cathetersthat surround a central lumen. Theapplicator is placed into the lumpectomycavity through a small incision.The physician expands thecatheter bundle by turning a mechanismfrom outside the breast. Thecatheters expand to form an ellipsoidalshape inside the cavity. Deliveryof radiation through the device'sindividual catheters allowsthe physician to better contour andcontrol the radiation dose.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.